You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Bay Area firm has built on its enzymatic barcoding technology to deliver a high-throughput, synthetic long-read library preparation technique.
The firm is hoping that researcher-generated data will soon be published in peer-reviewed papers, while it weathers the COVID-19 pandemic.
Mission Bio will use a recent $70 million funding round to develop quality control assays using its Tapestri single-cell analysis platform.
IncellDx is also developing a suite of COVID-19 diagnostic products to answer long-term questions about the treatment of patients still suffering from the disease.
Coastal Genomics owns the Ranger gel electrophoresis technology to collect specific DNA target sizes, with applications in noninvasive prenatal testing and oncology.
According to the company, the test has shown to be more sensitive and accurate than a COVID-19 anterior nasal swab test in the firm's EUA validation study.
The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.
A number of diagnostic labs have considered saliva-based SARS-CoV-2 testing but decided against it, while other groups continue to pursue it.
The tube, cap, and multitube consumables enable SARS-CoV-2 tests on its automated Panther and Panther Fusion sample-to-answer molecular diagnostic systems.
Cities and start-ups are pushing to incorporate SARS-CoV-2 wastewater monitoring into pandemic responses even as basic science researchers scramble to hammer out methods.
The targeted sequencing assay analyzes 12 genes and can be paired with the firm's BRCA gene testing kit.
Users will be able to sequence over 20,000 samples simultaneously with the updated panel, which the firm expects to offer sometime in the third quarter for research use only.
FBB Biomed, cofounded by a diagnostics industry veteran, is attempting to develop a blood RNA test to predict COVID-19 disease severity.
The Bay Area startup is offering a no-touch method to separate cell populations for downstream analysis in genomics and synthetic biology applications.
A US District Court will prevent BGI from distributing and promoting certain sequencing instruments that allegedly infringe Illumina patents.
The firm touts a new hybridization probe design, which it says will enable small, focused panels that reduce sequencing costs and assay time.
The firms are targeting a compatible offering for single-cell gene expression screens following CRISPR-based editing, with applications in drug discovery.
Akadeum's microbubble technology and NanoCellect's Wolf cell-sorting platform will be integrated for high-quality single-cell sequencing of rare cell types.
The company said it has also received Emergency Use Authorization from the US Food and Drug Administration for its nucleic acid extraction kit.
The technologies, called non-extensible oligonucleotides and linear DNA assembly, may help the sample prep firm improve existing products.
Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.
The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.
The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.
In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.